Table 2

Clinical efficacy in patients grouped by baseline CRP levels: <10 mg/L and ≥10 mg/L

WeekBaseline CRP levels <10 mg/LBaseline CRP levels ≥10 mg/L
Pooled secukinumab
150 mg (N=110)
Pooled placebo
(N=102)
Pooled secukinumab
150 mg (N=87)
Pooled placebo
(N=93)
ASAS20, %1651.8**29.472.4****28.0
15663.083.3
ASAS40, %1633.6***9.847.1****15.1
15644.570.3
BASDAI, mean change from baseline16−1.99****−0.86−2.78****−0.62
156−2.73−3.62
BASDAI50, %1630.0**10.841.4****7.5
15646.061.8
ASDAS inactive disease, %1620.0**4.912.6*1.1
15628.915.6
ASAS partial remission, %1616.4**2.912.6*4.3
15621.731.1
  • *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs placebo; missing values were imputed as non-response at week 16. MI and MMRM data presented at week 156 included n=88 and 71 in baseline CRP levels <10 mg/L and ≥10 mg/L, respectively. For BASDAI, LS mean change from baseline was presented using MMRM at weeks 16 and 156.

  • ASAS, Assessment of SpondyloArthritis international Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; LS, least squares; MI, multiple imputation; MMRM, mixed-effect model repeated measures; N, number of patients included in this pooled study at week 16; n, number of patients in this pooled study at week 156.